Since the introduction of disulfiram in 1951 (the first ever Food and Drug Administration (FDA)-approved medication for substance use disorders (SUDs)) (1), only seven other individual medications have been approved for the treatment of SUDs. While the repurpose of medications and different formulations increase the total number of FDA-approved medicines (Table 1 and(2)), the arsenal of...
Introduction Substance use disorder (SUD) is a major global health issue, contributing significantly to the disease burden. Despite this, effective treatments for SUD remain limited. Ketamine has shown potential as a treatment, yet no meta-analysis has assessed its efficacy for SUD. This study aimed to evaluate the efficacy and safety of ketamine in treating SUD. Methods Multiple databases were...
Substance use disorders (SUDs) affect the lives of more than 35 million people worldwide, according to 2019 data from the United Nations Office on Drugs and Crime. Current evidence suggests that MBIs may mitigate the harmful psychosocial effects associated with SUDs. Although MBIs have been extensively studied for efficacy, there remains a growing need to synthesize evidence from relevant...
Abstract Gaming addiction is a complex phenomenon that extends beyond behavioral reinforcement and neurochemical dysregulation. This study adopts a phenomenological approach, integrating Husserl’s active and passive synthesis with Heidegger’s existential structures and Arvidson’s conceptualization of attention, to explore how gaming addiction reshapes reflective awareness, attentional control...
Background Substance use disorders (SUDs) and treatment-resistant depression (TRD) remain a major global health challenge, marked by high relapse rates and limited long-term effectiveness of existing treatments. Ketamine, a glutamatergic modulator with rapid neuroplastic effects, has emerged as a novel intervention for TRD and is increasingly investigated as an adjunctive treatment for...
INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...
Background: Opioid use disorder remains a major public health and healthcare-system challenge in Tennessee, where many adults remain untreated, undertreated, or poorly retained in care. Medically monitored ibogaine has been proposed as a potential intervention for OUD, but its economic implications in a state treatment environment have not been well characterized. We evaluated the health and...
Substance use disorders (SUDs) represent a persistent global public health burden for which existing pharmacological and behavioral interventions show limited long-term efficacy across various patient populations (Sinha, 2011). Psilocybin-assisted therapy (PAT) has reemerged as a promising therapeutic treatment approach and has had renewed clinical interest with a growing amount of research...
Substance use disorder (SUD) is typically treated using biomedical and psychosocial approaches that focus on reducing symptoms, regulating neurobehavioral processes, and managing behavior. While these approaches are effective for many individuals, they may not fully address the deeper challenges associated with long-term substance use, such as existential distress, disruptions in identity, and...
Social media addiction has become an area of increasing research interest over the past decade. Many factors and variables are associated with the development of social media addiction, as well as others that have remained unexplored. Therefore, the present study examined some of these novel factors. More specifically, the study examined whether happiness mediated the association between...